Bicara Therapeutics Inc.
15.88-1.21 (-7.08%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · BCAX · USD
Key Stats
Market Cap
867.25MP/E (TTM)
-Basic EPS (TTM)
-4.66Dividend Yield
0%Recent Filings
8-K
Bicara Q2 results and trial updates
Bicara Therapeutics reported Q2 2025 net loss of $27.4 million, up from $17.0 million last year, driven by ramped-up R&D spending on ficerafusp alfa trials. Updated Phase 1/1b data at ASCO 2025 showed 54% ORR and 21.7-month median DOR in HPV-negative HNSCC patients. Cash stands at $436.6 million, funding operations into H1 2029. Additional data expected Q4 2025 to Q1 2026. Clinical progress fuels pivotal trial momentum.
10-Q
Q2 FY2025 results
Bicara Therapeutics posted a Q2 net loss of $27.4 million, up 61% y/y from $17.0 million, driven by R&D expenses climbing 57% to $24.8 million on clinical trial ramp-up and headcount growth, while G&A rose 85% to $7.2 million amid public company costs. YTD through June 30, 2025, losses widened to $64.2 million from $29.6 million, with R&D surging 112% to $59.1 million fueled by manufacturing and FORTIFI-HN01 Phase 2/3 trial enrollment. Cash burned $53.1 million in H1, leaving $436.6 million at quarter-end, sufficient into mid-2029 per management. No debt; free cash flow not disclosed in the 10-Q. Ongoing Y-Trap patent litigation poses inventorship risks to ficerafusp alfa. Clinical delays could stall pipeline progress.
8-K
Annual meeting results
Bicara Therapeutics held its 2025 annual meeting on June 9, with 87% of shares present. Stockholders elected Kiran Mazumdar-Shaw, Jake Simson, and Ryan Cohlhepp as class I directors for three-year terms, despite significant withheld votes for Mazumdar-Shaw and Simson. They also ratified KPMG LLP as auditors for the year ending December 31, 2025. Meeting passed smoothly.
8-K
Expands Boston office space
Bicara Therapeutics expanded its Boston headquarters on June 2, 2025, by subleasing 9,682 square feet from J.W. Childs Associates, effective June 4 after landlord consent. Base rent starts at $532,510 annually, rising to $554,023 by year three, with a $45,263 security deposit and term ending June 30, 2027. This bolsters operational capacity amid growth. Yet standard defaults loom.
10-Q
Q1 FY2025 results
Bicara Therapeutics posted a net loss of $36.8 million for Q1 FY2025 ended March 31, 2025, up from $12.5 million a year earlier, driven by ramped-up R&D spending on its lead candidate ficerafusp alfa. Operating expenses climbed to $41.8 million from $15.4 million, with R&D surging 172% y/y to $34.3 million on manufacturing and clinical trial costs for the pivotal FORTIFI-HN01 Phase 2/3 study in head and neck cancer, while G&A rose 123% to $7.5 million amid public company expenses. Interest income offset some pain, hitting $5.0 million versus $2.9 million last year, thanks to a larger cash pile. Cash burned $28.1 million in operations, leaving $462.1 million on hand—enough to fund through mid-2029. No debt weighs on the balance sheet. Yet clinical trials carry uncertain outcomes.
ATRA
Atara Biotherapeutics, Inc.
14.06-1.15
AURA
Aura Biosciences, Inc.
6.14-0.23
BCAB
BioAtla, Inc.
0.70-0.04
BCTX
BriaCell Therapeutics Corp.
12.44-0.90
BCYC
Bicycle Therapeutics plc
8.18-0.04
BOLT
Bolt Biotherapeutics, Inc.
5.86+0.14
CDTX
Cidara Therapeutics, Inc.
104.68-0.46
CNTX
Context Therapeutics Inc.
1.15-0.02
ELTX
Elicio Therapeutics, Inc.
9.40-0.34
TARA
Protara Therapeutics, Inc.
5.20+0.11